Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173080 · ClinicalTrials.gov registry record
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 594
- Enrollment target
NCT02173080: Completed study, sponsored by Mayo Clinic.
NCT02173080 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 594 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173080 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 594 participants
- Enrollment target
Study Summary
This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).
Primary Outcome
total score on the PLD-Q
Interventions
- OTHER PLD-Q
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2014-06 |
| Est. Completion | 2024-03-11 |
What the finished NCT02173080 record still lists
NCT02173080 is an observational study that tracks outcomes without assigning an intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PLD-Q is the first listed.
NCT02173080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02173080 about?
NCT02173080 is a clinical study titled "Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).". This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is commo...
What is the current status of trial NCT02173080?
This trial is currently completed. The enrollment target is 594 participants. The study started on 2014-06. Estimated completion is 2024-03-11.
What interventions are being tested in trial NCT02173080?
The interventions under investigation include: PLD-Q (OTHER).
Who is sponsoring clinical trial NCT02173080?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia